EI
DMAC icon

EAM Investors’s DiaMedica Therapeutics DMAC Stock Holding History

EAM Investors’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$619K Hold
91,425
– – 0.07% 247
2025
Q4 		$728K Buy
+91,425
New +$684K 0.08% 238
2023
Q4 		– Sell
-212,512
Closed -$548K – 277
2023
Q3 		$548K Sell
212,512
-57,907
-21% -$186K 0.11% 268
2023
Q2 		$1.17M Buy
+270,419
New +$657K 0.22% 212
2021
Q2 		– Sell
-108,232
Closed -$990K – 346
2021
Q1 		$990K Sell
108,232
-1,753
-2% -$16.4K 0.15% 305
2020
Q4 		$1.11M Buy
+109,985
New +$602K 0.18% 252

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

EAM Investors's DMAC Position: Q1 2026 in Review

EAM Investors held its DiaMedica Therapeutics (DMAC) position steady in Q1 2026 at 91,425 shares worth $619K. The position accounts for 0.07% of the portfolio, ranked #247.

EAM Investors first reported a position in DMAC in Q4 2020 and has held it in 6 quarters since. The position peaked at $1.17M in Q2 2023. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • EAM Investors held 91,425 shares of DiaMedica Therapeutics worth $619K as of Q1 2026.
  • EAM Investors left its DiaMedica Therapeutics share count unchanged in Q1 2026.
  • DiaMedica Therapeutics made up 0.07% of EAM Investors's portfolio in Q1 2026, its #247 holding.
  • EAM Investors first reported a position in DiaMedica Therapeutics in Q4 2020 and has held it in 6 quarters since.
  • EAM Investors's DiaMedica Therapeutics position peaked at $1.17M in Q2 2023.
  • 98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.